""Pharmaceutical Quality Controls Market is valued at USD 6.95 Billion in 2020 and expected to reach USD 12.38 Billion by 2027 with the CAGR of 8.60% over the forecast period.""
Pharmaceutical Quality Controls Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Rising spending on pharmaceutical industry and launch of new medicinal products are some of the major factors driving the growth of the Global Pharmaceutical Quality Controls Market.
The quality control refers to the total of all procedures to make sure the identity and purity of a selected pharmaceutical. Quality control is used to perform the pharmaceutical business. The pharmaceutical quality control liableness and accuracy area unit is an essential function of the pharmaceutical industry. Drug makers should completely check materials, processes, equipment, techniques, environments and personnel so as to make sure their final products area unit consistent, safe, effective and predictable. Quality control involves testing of units to approval for the final product. For example, inspection is the common method used for quality control purposes not only in production but also in services. Another example is statistical quality control which is an advanced method or technique used to control the quality of a product.
Global Pharmaceutical Quality Controls Market report is segmented on the basis of product, analysis type, product tested and by regional & country level. Based upon product, global pharmaceutical quality controls market is segmented into consumables, instruments and services. Based upon analysis type, global pharmaceutical quality controls market is segmented into sterility testing, bioburden testing, endotoxin testing, stability testing, extractable & leachable testing, raw material testing, others. Based upon product tested, global pharmaceutical quality controls market is segmented into vaccines, plasma product, drugs
The regions covered in this pharmaceutical quality controls market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of pharmaceutical quality controls is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Eurofins Expanded its Leadership in Biopharmaceutical Services with the Acquisition of PHAST in Germany
May 9th, 2018; Eurofins Scientific, announced the acquisition with PHAST Gesellschaft für Pharmazeutische Qualitätsstandards mbH (“PHAST”), one amongst Europe’s leading service suppliers within the field of pharmaceutical product quality. PHAST is best noted for its finished product testing business, wherever it is a strategic partner to medium and huge (bio) pharmaceutical corporations. PHAST provides pharmaceutical services with attention on internal control (QC) testing of little and huge molecules, and analytical development services. The acquisition of PHAST can complement Eurofins’ BioPharma Product Testing capabilities and expand Eurofins’ geographical footprint in these markets.
Rising spending on pharmaceutical industry and launch of new medicinal products, are some of the major factors driving the growth of the global pharmaceutical quality controls market. The global pharmaceutical market will reach nearly USD 1,430 billion by 2020, According to International Federation of Pharmaceutical Manufacturers & Associations. In addition, there is a high demand for pharmaceutical quality controls due to occurrence of COVID-19 globally. Quality control is an essential operation of the pharmaceutical industry to ensure the identity and purity of a particular pharmaceutical. For instance; the U.S. biopharmaceutical industry has been the world leader in the development of new medicines, The members of the Pharmaceutical Research and Manufacturing Association had invested an estimated $102 billion in research and development in 2018 continue to be at the forefront.
The biopharmaceutical industry invested an estimated USD102 billion in researches and development (R&D) in 2018 for establishing the biopharmaceutical sector. This increasing investments and product development are also fostering the market growth. According to National Conference of State Legislatures, as of 2015, about 36 % of total pharmaceutical spending in the commercial market was devoted to specialty medications. In 2017, FDA announced the Drug Competition Action Plan (DCAP) to further boost robust and timely market competition for generic drugs and help bring greater efficiency and transparency to the generic drug review process.
Additionally, though this plan FDA is helping remove barriers to generic drug development and market entry in an effort to incentive competition so that consumers can get access to the medicines. For instance; new drug therapy to help a wide range of patients suffering from many different medical conditions, rare disorders to common diseases approved by FDA’s Center for Drug Evaluation and Research’s (CDER’s) in 2017.
However, technical issues associated with quality control systems is the major restrains of the global pharmaceutical quality controls market. In spite of that, technological advancements and improvement in quality control system, changes in drug policies and regulations by government may generate new opportunities for pharmaceutical quality controls market growth.
North America is expected to dominate the global pharmaceutical quality controls market with highest shares followed by Europe, due to heavy investment in R&D expenditures, technological expansions and integration of innovative technologies and presence of major players in this region. In 2017, a wide variety of drug therapies to improve the health of the American public approved by The Center for Drug Evaluation and Research (CDER). According to International Federation of Pharmaceutical Manufacturers & Associations, The United States share of the global market will increase from 40.3% to 41% in2015 to 2020. As per study report, the research-based pharmaceutical industry currently spends over USD 149.8 billion on R&D per year. Thus, a heavy investment in R&D for the pharmaceutical industry is expected to drive the pharmaceutical quality controls market over the forecast period. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2017, the research-based pharmaceutical industry invested an estimated € 35,200 million in R&D in Europe.
Asia Pacific market is expected to witness a significant growth majorly due a rise in investment for the pharmaceutical industry and rising adoption of advanced technologies in this region. According to research report, there is rapid growth in the market and research environment in emerging economies such as Brazil, China and India, during the period 2013-2017 the Brazilian, Chinese and Indian markets grew by 11.5%, 9.4% and 11.0% respectively.
|2015 - 2020
|2021 - 2027
|Market Size in 2020:
|USD 6.95 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2027:
|USD 12.38 Billion
|Tables, Charts & Figures:
|Sartorious AG, WuXi AppTec, bioMérieux SA, Inc., Charles River Laboratories International, Toxikon Corporation Thermo Fisher Scientific, Inc., Merck KGaA, SGS S.A., Eurofins Scientific and others
|By Product, By Analysis Type, By Product Tested
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
By Analysis Type:
By Product Tested:
The Middle East and Africa
Frequently Asked Questions (FAQ) :
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®